Page 56 - GUÍA CLÍNICA HPN 2023
P. 56
Actualización 2023
56
9. Kelly RJ, Höchsmann B, Szer J, et al. Eculizumab in
Pregnant Patients with Paroxysmal Nocturnal Hemo-
globinuria. N Engl J Med. 2015;373(11):1032-1039. PMID:
26352814.
10. Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab
on hemolysis and transfusion requirements in patients
with paroxysmal nocturnal hemoglobinuria. N Engl J
Med. 2004;350(6):552-559. PMID: 14762182.
11. Hillmen P, Young NS, Schubert J, et al. The comple-
ment inhibitor eculizumab in paroxysmal nocturnal he-
moglobinuria. N Engl J Med. 2006;355(12):1233-1243.
PMID: 16990386.
12. Brodsky RA, Young NS, Antonioli E, et al. Multicenter
phase 3 study of the complement inhibitor eculizum-
ab for the treatment of patients with paroxysmal noc-
turnal hemoglobinuria. Blood. 2008;111(4):1840-1847.
PMID: 18055865.
13. Risitano AM, Marotta S, Ricci P, et al. Anti-complement
Treatment for Paroxysmal Nocturnal Hemoglobinuria:
Time for Proximal Complement Inhibition? A Position
Paper From the SAAWP of the EBMT. Front Immunol.
2019;10:1157. PMID: 31258525.
14. Risitano AM, Peffault de Latour R, Marano L, Frieri C.
Discovering C3 targeting therapies for paroxysmal
nocturnal hemoglobinuria: Achievements and pitfalls.
Semin Immunol. 2022;59:101618. PMID: 35764467.
15. Kulasekararaj AG, Kutter DJ, Griffin M, et al. Biomark-
ers and laboratory assessments for monitoring the
treatment of patients with paroxysmal nocturnal he-
moglobinuria: Differences between terminal and proxi-
mal complement inhibition. Blood Rev. 2023;59:101041.
PMID: 36732204.
16. Illingworth AJ, Marinov I, Sutherland DR. Sensitive and
accurate identification of PNH clones based on ICCS/
ESCCA PNH Consensus Guidelines-A summary. Int J
Lab Hematol. 2019;41 Suppl 1:73-81. PMID: 31069981.